Per Karlsson, MD, Gothenburg Universit, Gothenburg, Sweden, talks on what’s for the Profile for the Omission of Local Adjuvant Radiotherapy (POLAR), a 16-gene molecular signature developed to identify which patients with invasive breast cancer need radiation after breast conserving surgery. Prior to its use in clinical practice, POLAR must be validated in more trials. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.